---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-058326"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:46:05.148045+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance

## Summary
- Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.
- Previous non-compliance notice received Jan 19, 2023; extension granted Jul 19, 2023 to Jan 15, 2024.
- Company may consider reverse stock split; no assurance of regaining compliance.
- Failure to comply by deadline may result in Nasdaq delisting notice; Company can appeal.

## SEC filing metadata
- accession: 0001213900-23-058326
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390023058326/0001213900-23-058326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390023058326/ea182058-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-058326
- JSON: https://secwatch.observer/filing/0001213900-23-058326.json
- Plain text: https://secwatch.observer/filing/0001213900-23-058326.txt

## Key facts
- Listing & Compliance Notices
  Pasithea Therapeutics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: July 19, 2023, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to January 15, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841330/000121390023058326/0001213900-23-058326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.